Inaktiver Wert

Andere Sprachen Celsion Corporation Nasdaq

Aktien

US15117N3052

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

24.06.	Imunon, Inc. kündigt Datenbank-Sperre für Phase-2-Studie OVATION 2 mit IMNN-001 bei fortgeschrittenem Eierstockkrebs an	CI
05.06.	IMUNON, Inc. gibt bekannt, dass die ersten Teilnehmer in der klinischen Phase-1-Studie IMNN-101 geimpft wurden	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer	24.06.
Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer	24.06.
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial	05.06.
IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial	05.06.
Imunon : Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting entitled “A Phase II Study Evaluating the effect of IMNN-001 on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemother	03.06.
Imunon : Management Change/Compensation - Form 8-K	20.05.
Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024	20.05.
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting	15.05.
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study	13.05.
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study	13.05.
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update	13.05.
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO	08.05.
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024	08.05.
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024	08.05.
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024	06.05.
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	18.04.
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	18.04.
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101	18.04.
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	18.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Celsion Corporation Nasdaq

Aktien

US15117N3052

Andere Sprachen

Filter